Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Dyslipidemia
Interventions
DRUG

BMS-770767

Active, Oral, 15 mg, Daily, 28 days

DRUG

BMS-770767

Active, Oral, 50 mg, Daily, 28 days

DRUG

BMS-770767

Active, Oral, 150 mg, Daily, 28 days

DRUG

BMS-770767

Active, Oral, 50 mg BID, Daily, 28 days

DRUG

Placebo

Placebo, Oral, 0 mg, daily, 28 days

Trial Locations (14)

2077

Local Institution, Hornsby

2148

Local Institution, Blacktown

4101

Local Institution, South Brisbane

4510

Local Institution, Caboolture

5041

Local Institution, Daw Park

6004

Local Institution, Nedlands

72201

Harrell, Robert, Little Rock

78229

Cetero Research - San Antonio, San Antonio

E2A 4X7

Local Institution, Bathurst

L6T 3J1

Local Institution, Brampton

M8V 3X8

Local Institution, Toronto

C1A 5Y9

Local Institution, Charlottetown

J7J 2K8

Local Institution, Mirabel

H3J 2V5

Local Institution, Montreal

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY